Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of IDE196 and binimetinib in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer

Next Previous
Search
Trial Profile

A clinical study of IDE196 and binimetinib in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Darovasertib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors IDEAYA Biosciences

    • Most Recent Events

    • 09 Jul 2020 According to an IDEAYA Biosciences media release, interim data expected in late 2021 to early 2022.
    • 09 Jul 2020 Status changed from planning to recruiting, according to an IDEAYA Biosciences media release.
    • 09 Jul 2020 According to an IDEAYA Biosciences media release, first patient has been dosed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top